Evidence map›Paper›PMID 41814386›Full record

ArticleCardio-oncology (London, England)2026

Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.

Orly Leiva, Steven Soo, Olivia C Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Orly LeivaGill Heart & Vascular Institute, University of Kentucky College of Medicine, 800 Rose St, Lexington, KY, 40508, USA. orly.leiva@uky.edu.
Steven SooDepartment of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Olivia C LiuDivision of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Victor YouDivision of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Andrew PalmerDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Justin KahlaDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Yasmeen MurtazaDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Olatoyosi OdenikeDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Anand PatelDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Jeanne DeCaraDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Mark BelkinDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Manreet KanwarDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Leo GozdeckiDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Stanley SwatDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Michelle Hyunju LeeDivision of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Joan HowDivision of Hematology & Oncology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, Boston, USA.
Gabriela HobbsDivision of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. ghobbs@partners.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMyelofibrosis (MF) is a type of myeloproliferative neoplasm (MPN) that is associated with significant morbidity and mortality including progression to acute leukemia and cardiovascular disease (CVD). High-output heart failure (HOHF) has been previously associated with MF, though its impact on outcomes is unknown.

aimsTo investigate the impact of HOHF on outcomes among patients with MF. METHODS AND

resultsThis was a multicenter retrospective cohort study of MF patients from 2010-2024 with ≥ 1 transthoracic echocardiogram (TTE). Doppler estimation of cardiac index on TTE and pulmonary artery systolic pressure (PASP) was estimated and HOHF was defined as cardiac index of ≥ 3.54 L/min/m2 and PASP > 40 mmHg. Patients with vs without HOHF were compared. Primary outcome was death or leukemia transformation. Multivariable Cox proportional hazards regression was performed to explore association between HOHF and primary outcome. Of 114 patients included, 19 (16.7%) had HOHF, 46 (40.4%) were female. Patients with HOHF were more likely to have secondary MF and lower hemoglobin levels. After Cox proportional hazards regression modeling, HOHF was associated with increased risk of primary outcome (aHR 2.86, 95% confidence interval 1.01 – 8.09).

conclusionsAmong patients with MF, HOHF was associated with increased risk of death or leukemia progression. These findings suggest that echocardiographic evaluation of patients with MF for HOHF may aid in the identification of patients at risk of hematologic progression or poor outcomes, in addition to traditional risk factors. Prospective studies are needed to investigate the utility of echocardiographic screening for patients with MF.

Indexed as

Cardio-OncologyEchocardiographyHeart failureHemodynamicsMyelofibrosisMyeloproliferative neoplasms

Identifiers

PMID41814386
PMCPMC13094197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.